BACKGROUND

About one-third of the world population has latent TB infection (LTBI), with 13 million people (4.2% of the population) affected in the United States. People with LTBI, especially those who are HIV-positive, are at increased risk of developing active TB disease. In the U.S., about 6% of all active TB cases (up to 10% among people aged 15-44) occur among persons who are HIV-positive.

New, recently approved by the FDA, 12-dose treatment regimen of once-weekly saturated and rifapentine for 3 months (DOT) by directly observed therapy (DOT), is safe and effective for treating latent tuberculosis infection. Treatment completion with 3HP by DOT is high (as much as 82.1% in the TBTC Prevent TB study). However, widespread implementation of 3HP has been limited by the requirement for DOT.

RESULTS

Of 1,065 patients enrolled, 4 were excluded as contacts to drug-resistant TB, 908 were eligible to complete treatment, and 772 (77%) were enrolled in the study. The study arms were demographically similar. Median age was 27 years [28-27]. Participants included 492 (69%) women, 344 (44%) contacts to active TB, and 641 (14%) LTBI tuberculin converters; 85 (9%) had diabetes, 11 (1%) were HIV-positive, 776 (10%) HIV-negative, and 281 (34%) HIV-unknown. All treatment arms were balanced in respect to sociodemographic and clinical characteristics of enrolled study participants.

Overall treatment completion was 87.2% [95% CI 83.1-90.5] by DOT, 74.0% [95% CI 70.6-76.9] by SAT, and 76.4% [95% CI 71.9-80.9] by eSAT. Treatment completion in US participants was 86.4% [95% CI 84.0-88.9], 77.9% [95% CI 72.6-83.2], and 76.7% [95% CI 70.8-80.5] respectively.

For primary analysis, only the first enrolled (randomized) participant at each household was included. Results of the primary analysis of treatment completion are presented in Table 1.

DOT was non-inferior to DOT in the US, but not overall, and eSAT did not achieve non-inferiority (Figure 1). Discontinuation rates due to adverse effects were similar by arm, 3.6% DOT, 5.4% SAT, 4.3% eSAT (P=0.15). Reported adverse events are presented in Table 2.

CONCLUSIONS

We found support the use of 3HP by SAT in the US. Non-inferiority was not established for SAT or eSAT overall due to higher than predicted DOT completion rates and variability in SAT and eSAT completion outside the US. Further cost-effectiveness analyses and evaluation of the role of text reminders are needed.

METHODS

The study was a multi-center (12 sites) international (U.S., Spain, Hong Kong, South Africa) randomized clinical trial among adults with LTBI and no contraindications to 3HP or SAT.

Randomization to DOT, SAT, eSAT treatment groups was 1:1:1, blocked (with variable size blocks), stratified by recruitment site. A non-inferiority margin (delta) of 15% was used. The margin was selected based on cost-effectiveness analyses conducted based on data from the U.S.

Concomitant use of participants from same household was allowed only if the household had no exposed 2 patients. First participant from the household was randomized, other members of the household were assigned into same treatment group.

In order to have adequate statistical power for a pre-planned analysis of U.S. population only, the study targeted to enroll at least 75% of study participants in U.S.-based sites. The primary outcome of the study was completion of study therapy, which was defined as completion of 11 or more treatment doses (combination of 900 mg of saturated and 900 mg of rifapentine) within 16 weeks, as determined by clinic dose records and pill counts for DOT, and by self reports, pill counts, and Medication Event Monitoring System (MEMS) data for SAT and eSAT.

RESULTS

Of 1,065 patients enrolled, 4 were excluded as contacts to drug-resistant TB, 908 were eligible to complete treatment, and 772 (77%) were enrolled in the study. The study arms were demographically similar. Median age was 27 years [28-27]. Participants included 492 (69%) women, 344 (44%) contacts to active TB, and 641 (14%) LTBI tuberculin converters; 85 (9%) had diabetes, 11 (1%) were HIV-positive, 776 (10%) HIV-negative, and 281 (34%) HIV-unknown. All treatment arms were balanced in respect to sociodemographic and clinical characteristics of enrolled study participants.

Overall treatment completion was 87.2% [95% CI 83.1-90.5] by DOT, 74.0% [95% CI 70.6-76.9] by SAT, and 76.4% [95% CI 71.9-80.9] by eSAT. Treatment completion in US participants was 86.4% [95% CI 84.0-88.9], 77.9% [95% CI 72.6-83.2], and 76.7% [95% CI 70.8-80.5] respectively.

For primary analysis, only the first enrolled (randomized) participant at household was included. Results of the primary analysis of treatment completion are presented in Table 1.

DOT was non-inferior to DOT in the US, but not overall, and eSAT did not achieve non-inferiority (Figure 1). Discontinuation rates due to adverse effects were similar by arm, 3.6% DOT, 5.4% SAT, 4.3% eSAT (P=0.15). Reported adverse events are presented in Table 2.

CONCLUSIONS

We found support the use of 3HP by SAT in the US. Non-inferiority was not established for SAT or eSAT overall due to higher than predicted DOT completion rates and variability in SAT and eSAT completion outside the US. Further cost-effectiveness analyses and evaluation of the role of text reminders are needed.